Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

le
0
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

 Programs progressing in line with strategy
 Significant reduction of net loss: ?12.2 million compared to ?28.1 million in H1 2015
 ?33.4 million in cash and cash equivalents as of June 30, 2016
 Cash burn guidance confirmed around ?35 million in 2016

Conference call scheduled in English on September 6th, 2016 at 06:00 PM CET (12:00 PM EST)


Strasbourg, France, September 5, 2016, 5:35 pm CET - Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced its financial results for the six-month period ended June 30, 2016 and published an update on its business and on the development of its portfolio of therapeutic vaccines and oncolytic viruses.
…/…

Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.

Pour consulter le fichier PDF en intégralité, cliquez ici.

Pour visualiser les documents au format PDF, vous pouvez télécharger gratuitement Acrobat Reader XI.


Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant